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In a study of apparently normal, healthy Korean Army recruits performed in 1962, we found that 42 of
1,906 screened subjects had elevations of their serum glutamic pyruvate transaminase. Liver biopsies were
obtained from 32 of these subjects and 9 of these had a "novel" antigen present, which reacted specifically
with a convalescent serum from a case of serum hepatitis. We have recently tested frozen serum obtained
from 8/9 of these cases and found that all 8 had HBsAg in their serum which, in some cases, persisted for at
least three months. We reviewed the histological specimens from the original 32 cases using newly defined
criteria: 18 were diagnosed as chronic active hepatitis and the 8 HbsAg positive cases with the "novel"
antigen were in this group. In four of these cases the lesion appeared to progress to cirrhosis during a 34
month follow-up period. Since none ofthe cases had a prior history ofhepatitis and no symptoms developed
during the follow-up period, our findings emphasize the significance ofchronic hepatitis B virus carrier state
in the etiology of cryptogenic cirrhosis.
INTRODUCTION
In February of 1962 a large-scale serum transaminase survey was carried out
among 1,906 Korean army recruits in a training center in Nonsan, South Korea. [1].
Serum glutamic pyruvic transaminase (SGPT) elevations of greater than 50 Sigma
units were found in 42 subjects, 32 of whom were then hospitalized for an average
period ofthree months. During this time extensive clinical and laboratory investiga-
tions, including three needle liver biopsies, were performed on each patient. These
studies documented a syndrome of subclinical chronic active hepatitis characterized
histologically in the majority ofcases by what is now generallytermed"chronic active
hepatitis" [2-4]. In four cases subclinical progression to cirrhosis was noted in the
course of serial biopsies.
In 1963 a similar but larger studyconfirmed the highfrequency ofthis syndrome in
clinically well Oriental populations and further documented the progression of this
disease to typical cryptogenic cirrhosis [5].
To investigate the etiology ofthis syndrome, Prince, Fuji, and Gershon carried out
immunohistochemical studies on liver biopsies obtained from these patients. These
studies identified hepatitis B associated antigen(s) in the liver cells of nine of the 32
biopsied cases [6]. Antigen was detected by the immunofluorescent complement
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fixation technique, utilizing a pool of convalescent serum from Korean cases of
icteric hepatitis as a presumptive source of antibody. It was suggested that the
subclinical chronic active hepatitis syndrome was a manifestation of the hepatitis B
virus carrier state. However, the possibility that these findings reflected unusual
autoantibodies, and that this disease may have been caused by chronic chemical
injury, such as that which might be caused by chronic chemical injury, such as that
which might be caused by ingestion of mycotoxins, could not be totally excluded at
that time.
Due tothelack ofaless cumbersome immunologictest for hepatitis B virus(HBV),
publication of the above work excited neither great interest nor attempts at
independent confirmation. However, the availability of new tests for hepatitis B
associated antigens, i.e., the hepatitis B surface antigens (HBsAg) and the hepatitis B
core antigen (HBcAg), provided new approaches for reinvestigation ofthis problem.
Utilizing human and animal antisera-containing antibody against HBsAg (anti-
HBs), several workers have investigated the localization of this antigen in livers of
patients with type B hepatitis orwith the chronic hepatitis B virus carrier state [7-11].
The antigen localization described by most ofthese workers was strikingly similar to
that which had been observed in the Korean study in 1962.
Recently we have had an opportunity to re-examine the 14 remaining original
serum specimens of the Korean patients with chronic active hepatitis, including nine
in whom cellular localization of the putative hepatitis B specific antigen had been
demonstrated.
The present report will review the findings of the Korean study utilizing histologic
classification for chronic liver disease, which have been elucidated subsequent to our
original publications. We will provide the results oftesting the available sera for the
hepatitis B related antigens [12-15] and antibodies, i.e., HBsAg and anti-HBs, and
antibody to the hepatitis B core antigen (anti-HBc). The report will document that
more than half of the cases of chronic anicteric hepatitis in the Korean study had
subclinical chronic active hepatitis associated with the chronic hepatitis B virus
carrier state.
MATERIALS AND METHODS
Patients
Patients were selected from 1,906 Korean Army recruits on the basis of results
obtained bytestingoffreshly drawn serum for SGPT as described in detail previously
[1]. Thirty-two recruits with SGPT levels greater than 50 Sigma units on two
successive bleedings who gave their informed consent were hospitalized for studyfor
an average period ofthree months. The subjects were males ranging in age from 19 to
32 with an average of 24 years. None had a history of transfusion or illicit or
prescribed parenteral drug use.
Immunohistochemical Methods
The detailed immunohistochemical methods employed have been fully described
[6]. The immunofluorescent complement fixation technique was employed utilizing a
variety of sera as a source for antibody. The initial demonstration of antigen was
carried out with a presumptive antibody-containing pool of serum derived from 19
cases of convalescent icteric hepatitis occurring in Korean Army personnel. The
specificity of the observed staining was determined in the following manner:
1. Staining required active complement.
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PLATE 1. (Case 231) Immunofluorescent staining observed in different areas of the needle biopsy section. A.
Nuclear fluorescence (x 30)). B. Nuclear tluorescence (- 300). The arrow indicates a nucleus containing a crescent-
shaped zone of fluorescence which appeared as an amphophilic region when restained wsith haematoxylin and eosin
stain. C. Cytoplasmic staining only (x 675). )D. A tocus ot cells with both nuclear and cytoplasmic staining
(arrow), surrounded bv cells with nuclear staining only (circles) (x 300).THE ETIOLOGY OF CHRONIC ACTIVE HEPATITIS IN KOREA 161
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FIG. 1. Serum transaminase in three cases of HB associated chronic aggressive hepatitis. Note transient return of
SGPT to normal levels in Case 236.162 PRINCE AND GERSHON
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FIG. 2. Serum transaminase in three cases of HB associated chronic aggressive hepatitis. Note return of SGPT
values to normal levels in Case 251 concurrent with development of cirrhosis.THE ETIOLOGY OF CHRONIC ACTIVE HEPATITIS IN KOREA
TABLE I
Summary of Fluorescent Antibody and HB Serologic Results (32 Korean Army Recruits with SGPT > 50)
No. Fluorescent Proportion with
Histologic Diagnosis No. of Cases Antibody Positive HBsAg in Seruma
Chronic active hepatitis 18 8 10/12
Chronic persistent hepatitis 5 0
Nonspecific reactive hepatitis 4 0 -
Acute hepatitis I 0 1/1
Inadequate biopsy 4 1 1/1
TOTAL 32 9 12/14
aSerum from only 14 cases was available for these tests.
2. Staining was not demonstrated in control liver tissues from patients with
normal livers or from patients with acute or chronic liver disease suspected, on the
basis of clinical and epidemiologic data, not to be due to hepatitis B infection.
3. Antibody to the demonstrated antigens was not found in sera from cases
suspected to be due to infection with hepatitis type A or in conventional gamma
globulin. Antibody was, however, found in convalescent serum from a well-
documented case of long incubation period post-transfusion hepatitis.
Serologic Methods
Sera from the original series of cases which have been stored for 13 years at -70°C
were tested for the presence of HBsAg by agar gel diffusion (AGD) [14] and by the
Ausria I direct solid phase radioimmunoassay (RIA) [16] according to the instruc-
tions of the manufacturers (Abbott Laboratories, Chicago, IL). All positive RIA
results were tested for specificity by anti-HBs neutralization [17]. Sera employed as
sources of antibody in the original fluorescent antibody experiments were tested for
anti-HBs bypassive hemagglutination [18] and for anti-HBc byindirect immunofluo-
rescent test [19] utilizing as substrate sections of liver from a chronic HB carrierwho
died while on renal dialysis from causes unrelated to liver disease.
RESULTS
Figures 1 and 2 summarize results of serial transaminase determinations and serial
liver biopsies on six of the 12 cases subsequently found to be HBsAg carriers by
detection of antigen in their sera.
The predominant pattern was one of continuing transaminase abnormality with
occasional fluctuations to normal levels. The histologic findings confirmed the
chronic nature ofthe disease process, even in patients such as Case No. 251 in whom
transaminase declined continuously during hospitalization and remained within
normal limits for the last six weeks of hospitalization. Serial biopsies in this case
revealed chronic active hepatitis with progressive increase in the prominence of
fibrous septa. The third biopsy in this case revealed clear cut cirrhosis [3].
Table 1 summarizes the histologic diagnosis from the first biopsies of the 32
hospitalized cases in accordance with currently accepted histologic criteria [4].
Chronic active hepatitis was the predominant histologic picture and was seen in 18 of
the 32 cases. Five cases showed chronic persistent hepatitis, four showed non-specific
reactive hepatitis, one case showed a histological picture resembling that of acute
hepatitis, and in four cases the biopsy was inadequate for accurate classification.
163PRINCE AND GERSHON
Results ofImmunohistochemical Studies
Nine of the 32 cases examined showed focal nuclear (Plate 1A and B) and/or
cytoplasmic staining (Plate IC and D) of hepatic parenchymal cells when stained
with the complete staining system, i.e., convalescent serum from icteric hepatitis cases
plus fresh guinea pig serum followed by fluorescent conjugated anti guinea pig
globulin. Weaker staining was also seen when serum from the patients who provided
the biopsies was used as a source of antibody. However, no staining was seen when
conventional gamma globulin, or a variety of other control sera, including acute and
convalescent sera from three cases of hepatitis type A, were employed as a source of
antibody. Strong staining was observed when serum from a classical case of long
incubation post-transfusion hepatitis type B was used as a source of antibody [6]. In
addition, staining was blocked by inactivation of the human and guinea pig serum
employed (560C, 30 minutes), thus indicating the complement dependence of the
staining system [6].
Further evidence supporting the specificity of the observed staining was derived
from utilization ofthe complete staining system to examine autopsy liver tissues from
patients with cirrhosis, Weil's disease, and diseases unrelated to the liver. These
tissues did not reveal the staining observed in the biopsies from chronic active
hepatitis patients.
It was noted that large foci of stained cells contained cells with nuclear and
cytoplasmic staining, or cytoplasmic staining alone, and that cells on the periphery of
these foci usually revealed only nuclear staining. The two forms ofstaining suggested
that different stages of infection were being observed.
Results of Testsfor Hepatitis B Related Antigens in Patient Sera (Table 2)
In 1973, 13 years after the original study, only 14 sera were available from the 32
hospitalized cases. These included sera from the nine cases in whom the hepatitis B
associated antigens had been demonstrated by the fluorescent antibody method.
HBsAg was detected in serum from four cases by agar gel diffusion and in an
additional eight cases by radioimmunoassay. In two cases there was insufficient
serum for definitive testing. Thus, HBsAg was present in at least 12 of the 14 cases,
confirming the original postulate that these patients were hepatitis B carriers. In three
cases the persistence of detectable HBsAg was documented for at least 90 days and in
two additional cases for 60 days.
Results of Testingfor Anti-HBs and Anti-HBc in the Antiserum
Usedfor Fluorescent Antibody Tests
The convalescent serum pool used for fluorescent staining in 1962 was retested in
1974 for content of anti-HBs by the passive hemagglutination test, and for anti-HBc
by the indirect immunofluorescence test. The antibody titers found in these tests
(Table 3) were sufficient to account for the fluorescent antibody staining observed in
1962.
DISCUSSION
The similarity between results presented in recent studies of localization of
hepatitis B related antigens in liver tissues [7-11], and those which were obtained in
the present study in 1962, as well as data which we had obtained suggesting that the
antigens demonstrated in Korean chronic active hepatitis were specific for hepatitis B
infection [6] suggested that the antigen described in 1962 and the more recently
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TABLE 2
Results of HBsAg Determination in Sera Collected in 1962 from 14 Cases of Anicteric Hepatitis in Korea
Tests for HB Antigen
Radioimmunoassay Immunofluorescence (1962)
Case # +/ Nuclear Cytoplasm
No. Histologic Diagnosis AGD # Tested S.D.
a (% Cells) (% Cells)
230 Acute hepatitis + QNS - -
231 Chronic active hepatitis (mild) - QNS - +(2) +(10)
234 Chronic active hepatitis (severe) - 1/1 104
235 Chronic active hepatitis (severe) - 1/1 12.9
236 Chronic active hepatitis (severe) + QNS - -
237 Inadequate biopsy + QNS - +(0.5) +(5)
239 Chronic active hepatitis (mild) - 1/1 121 +(0.5); +(5)
240 Chronic active hepatitis (severe) - 3/3 152 +(n.d.) +(n.d.)
127
146
244 Chronic active hepatitis (severe) - 1/ 1 121
249 Chronic active hepatitis (mild) - QNS - +(2) +(n.d.)
251 Chronic active hepatitis (severe) + 3/3 127 +(2) +(5)
with cirrhosis in final biopsy only 127
126
252 Chronic active hepatitis (mild) - 2/2 87 +(M) +(M)
133
254 Chronic active hepatitis (severe) - 3/3 122 +(M) +(5)
100
125
257 Chronic active hepatitis (mild) - 2/2 108 - +(5)
133
a Standard deviations from mean of negative controls.
defined hepatitis B related antigens might be identical. The presently reported
serologic data indicate that 12 of the 14 cases examined had detectable hepatitis B
antigen in their serum, providing additional evidence that the cases under study in
1962 were due to type B infection.
In the light of our present understanding [19] it seems likely that the cytoplasmic
staining observed in 1962 represented localization of HBsAg (now thought to
represent excess viral membrane) in the cytoplasm of infected liver cells and that the
nuclear staining represented localization of the core antigen [20] (HBcAg) of the
42 nm Dane particle which is thought to represent the complete hepatitis B virion
[21]. The fact that the centrally located cells of stainable foci showed both antigens,
while the cells on the periphery of these foci, which were probably more recently
infected, showed only nuclear staining, would be consistent with the expectation that
synthesis of nuclear nucleocapsid antigens precedes that of the cytoplasmic surface
antigens.
TABLE 3
Assay for HB Related Antibodies in the Convalescent Serum Pool Used for Immunofluorescent Staining in 1962
Antibody Test Titer
Anti-HBs Passive hemagglutination 1:160
Anti-HBc Indirect itnmunofluorescence 1:40166 PRINCE AND GERSHON
The presence of anti-HBc and anti-HBs in the convalescent serum pool used for
fluorescent antibody staining is not surprising in the light of recent reports. It is now
known that a strong anti-HBc response develops during the acute illness in HBV
infections [20,22]; anti-HBs usually appears somewhat later but does not generally
rise to high levels in primary HBV infection; high titers of anti-HBs are often,
however, observed in reinfected or chronically infected patients [23]. The convales-
cent serum pool probably contained sera from cases of all ofthe above types. Due to
the high sensitivity of the indirect fluorescent antibody techniques for detection of
antibody it is now not surprising that antibodies to both of these HB associated
specificities were readily detectable.
The documentation of a rapid progression of HB associated chronic active
hepatitis to cirrhosis among some of the patients studied in Korea in 1962, as well as
the already published detailed clinical, laboratory, and histologic characterization of
these patients [2,3] contributes to our emerging understanding of the medical
significance of the hepatitis B carrier state. These results indicate that the chronic
hepatitis B carrier state may be a significant etiologic factor in the development of
chronic active hepatitis and liver cirrhosis. The close association between these
entities [24] cannot be readily explained by superinfection of chronic liver disease
patients with hepatitis B virus since most chronic HBV carriers in high prevalence
regions acquire their infection very early in life, i.e., prior to development of chronic
liver disease [25]. Furthermore, there are now many well-documented cases in which
primary hepatitis B infection of newborn and older patients results in the sequence of
acute hepatitis, unresolved hepatitis, chronic active hepatitis, and cirrhosis. In some
cases the end result of this sequence is primary liver cancer.
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